Download Your Copy of the 2025 Agenda
The Obesity Drug Development Summit Europe is your unique forum to learn and network with the brightest minds revolutionising the industry.
50+
Industry Leaders Seeking to Make New Connections and Share Experiences
17+
Expert Speakers Sharing Insights from Leading Pharma, Pioneering Biotechs & Top Academic Institutions
2
Days of Cutting-Edge Content Featuring Deep Dives and Case Studies
5
Core Themes Across the Obesity Drug R&D Cycle: From Next-Gen Therapies, to Regulation
4
Roundtable Discussions to Share Perspectives with Industry Peers in an Intimate Setting
Having trouble downloading the brochure? Let us know and we’ll email it to you instead.
Shaping the Future of Obesity Drug Development: Innovation, Collaboration, and Breakthrough Science
The Obesity Drug Development Summit Europe 2025 was the premier forum for pharmaceutical leaders, biotech innovators, and academic pioneers to redefine the next generation of obesity therapies. Across three days of data-driven discussions, interactive workshops, and unparalleled networking, this summit tackled the most pressing challenges in metabolic health—from GLP-1 combinations and muscle-preserving therapies to RNA-based innovations and precision trial design.
60+ industry decision-makers joined in Barcelona to:
- Explore novel targets beyond GLP-1, including GIPR modulators, mitochondrial activators, and DNA-encoded therapies.
- Master payer-centric clinical trials with real-world evidence and multi-organ endpoints.
- Navigate manufacturing hurdles for oral formulations and extended-release injectables.
- Forge collaborations with key players like Novo Nordisk, Eli Lilly, and Boehringer Ingelheim.
With a focus on sustainable efficacy, patient adherence, and commercial success, this was your opportunity to shape the future of a $100 billion market.